Goldman Sachs Group (GS)

Elon Musk is going all-in on artificial intelligence.

Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, o

The SpaceX IPO has Wall Street debating trillion-dollar valuations. Luke Lango argues the selloff it triggered is actually the buying opportunity investors have been waiting for in Corning, Ciena, Broadcom, and Redwire.

What comes next for the iconic big box retailer?

CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-musc

It announced a $50 million accelerated share repurchase program.

SpaceX is hoping to raise $75 billion at a $1.77 trillion valuation.

Things would have to go perfectly for the next half-decade.

What Happened? A number of stocks fell in the afternoon session after Trump said a US-Iran deal could come in "two or three days," pulling energy equities sh...

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol

Alnylam Pharmaceuticals (NASDAQ:ALNY) executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst Salveen Richter. Jeff Poulton, Alnylam’s chief financial officer, said the company’s “Alnylam 2030”

What Happened? Shares of alternate site health provider Option Care Health (NASDAQ:OPCH) jumped 3.7% in the morning session after Goldman Sachs initiated cov...

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular dege

Goldman Sachs stayed in focus as GS stock traded near $1,045 on June 9, 2026, after another active market session. The stock was recently priced at $1,045.

Investors are being offered a new AI investment opportunity.

Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT. Mark Singleton, Bioventus’ senior vice president and chief financi

SpaceX says it may serve a $28 trillion market.

What Happened? Shares of health insurance company Oscar Health (NYSE:OSCR) jumped 10.8% in the afternoon session after the company provided a business update...

Semiconductor stocks are staging a comeback on Monday. Here's what's driving the rebound in Intel, Micron, and the broader market.

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate

Choosing between these two S&P 500 ETFs really comes down to how you feel about the tech sector.